公开(公告)号：US10183068B2

公开(公告)日：2019-01-22

申请号：US15311298

申请日：2015-05-15

Applicant: STC.UNM

Inventor： Pavan Muttil ,  Denis Wafula ,  Terry Wu ,  Nitesh Kunda ,  Dominique N. Price

IPC: A01N63/00 ,  A61K39/02 ,  A61K9/16 ,  A61K9/00 ,  A61K39/00

Abstract: This disclosure describes, generally, compositions and methods related to thermostable vaccine formulations, their storage, and their use. Generally, the thermostable vaccine formulations can be in the form of a dry powder. The dry powder formulations can increase the length of time that the vaccine remains viable under non-refrigerated, ambient temperature conditions.

公开(公告)号：US20180169009A1

公开(公告)日：2018-06-21

申请号：US15577572

申请日：2016-06-01

Applicant: Patrick JOHNSON ,  C. Jeffrey BRINKER ,  Eric CARNES ,  Graham TIMMINS ,  Pavan MUTTIL ,  STC.UNM

Inventor： Patrick Johnson ,  C. Jeffrey Brinker ,  Eric Carnes ,  Graham Timmins ,  Pavan Muttil

IPC: A61K9/00 ,  A61K9/16 ,  A61K47/54 ,  C08L23/22 ,  A61K9/12 ,  A61K9/127

CPC classification number: A61K9/0073 ,  A61K9/12 ,  A61K9/1271 ,  A61K9/1617 ,  A61K47/543 ,  C08L23/22

Abstract: This disclosure describes compositions, vaccine, and methods that involve a biocomposite material Generally, the biocomposite material includes a cell and a lipid-silica matrix at least partially encapsulating the cell. In some cases, the cell can be viable but not culturable (VBNC). In some cases, the lipid-silica matrix includes a dried sol and/or possesses ordered nanostructure.